Literature DB >> 23913216

Assessment of mRNA splice variants by qRT-PCR.

Ileabett M Echevarria Vargas1, Pablo E Vivas-Mejía.   

Abstract

Alternative splicing is an essential process for the generation of protein diversity. The physiological role, cellular localization, and abundance of splice variant products compared to the wild-type protein may be completely different. This is illustrated by the five splice variants of the antiapoptotic protein survivin that are more abundant in cancerous cells compared with normal tissues. Interestingly, some survivin splice variants have been associated with drug resistance. Herein, we describe a SYBR green I-based real-time PCR method to assess the messenger RNA levels of the human survivin splice variants in taxane-sensitive versus taxane-resistant ovarian cancer cells and in human ovarian cancer samples. Furthermore, in this chapter, we describe the quantification of survivin splice variants by real-time quantitative PCR (qPCR) after in vitro and in vivo small interference RNA (siRNA)-mediated silencing of survivin splice variants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913216      PMCID: PMC4060277          DOI: 10.1007/978-1-62703-547-7_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

3.  Differential subcellular localization of functionally divergent survivin splice variants.

Authors:  C Mahotka; J Liebmann; M Wenzel; C V Suschek; M Schmitt; H E Gabbert; C D Gerharz
Journal:  Cell Death Differ       Date:  2002-12       Impact factor: 15.828

4.  Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Authors:  Premal H Thaker; Sertac Yazici; Monique B Nilsson; Kenji Yokoi; Rachel Z Tsan; Junqin He; Sun-Jin Kim; Isaiah J Fidler; Anil K Sood
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

5.  Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody.

Authors:  Gerben Vader; Jos J W Kauw; René H Medema; Susanne M A Lens
Journal:  EMBO Rep       Date:  2006-01       Impact factor: 8.807

6.  Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.

Authors:  Diana E Lamendola; Zhenfeng Duan; Rushdia Z Yusuf; Michael V Seiden
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

Review 7.  Targeting survivin in cancer therapy: fulfilled promises and open questions.

Authors:  Marzia Pennati; Marco Folini; Nadia Zaffaroni
Journal:  Carcinogenesis       Date:  2007-03-06       Impact factor: 4.944

8.  Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.

Authors:  G Ferrandina; F Legge; E Martinelli; F O Ranelletti; G F Zannoni; L Lauriola; M Gessi; V Gallotta; G Scambia
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

9.  Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions.

Authors:  Frederique Ponchel; Carmel Toomes; Kieran Bransfield; Fong T Leong; Susan H Douglas; Sarah L Field; Sandra M Bell; Valerie Combaret; Alain Puisieux; Alan J Mighell; Philip A Robinson; Chris F Inglehearn; John D Isaacs; Alex F Markham
Journal:  BMC Biotechnol       Date:  2003-10-13       Impact factor: 2.563

10.  Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies.

Authors:  Hugo Caldas; Laura E Honsey; Rachel A Altura
Journal:  Mol Cancer       Date:  2005-03-02       Impact factor: 27.401

View more
  6 in total

1.  Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models.

Authors:  Rocco Sciarrillo; Anna Wojtuszkiewicz; Irsan E Kooi; Valentina E Gómez; Ugo Boggi; Gerrit Jansen; Gert-Jan Kaspers; Jacqueline Cloos; Elisa Giovannetti
Journal:  J Vis Exp       Date:  2016-12-09       Impact factor: 1.355

2.  MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.

Authors:  Mónica Rivera-Díaz; Miguel A Miranda-Román; Daniel Soto; Mario Quintero-Aguilo; Humberto Ortiz-Zuazaga; María J Marcos-Martinez; Pablo E Vivas-Mejía
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Suppressed diversity of survivin splicing in active rheumatoid arthritis.

Authors:  Minna Turkkila; Karin M E Andersson; Sylvie Amu; Mikael Brisslert; Malin C Erlandsson; Sofia Silfverswärd; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2015-07-10       Impact factor: 5.156

4.  Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Miguel A Miranda-Román; Yasmarie Santana-Rivera; Fatma Valiyeva; Mónica Rivera-Díaz; María J Marcos-Martínez; Pablo E Vivas-Mejía
Journal:  Cancers (Basel)       Date:  2018-10-12       Impact factor: 6.639

5.  Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.

Authors:  Yasmarie Santana-Rivera; Robert J Rabelo-Fernández; Blanca I Quiñones-Díaz; Nilmary Grafals-Ruíz; Ginette Santiago-Sánchez; Eunice L Lozada-Delgado; Ileabett M Echevarría-Vargas; Juan Apiz; Daniel Soto; Andrea Rosado; Loyda Meléndez; Fatima Valiyeva; Pablo E Vivas-Mejía
Journal:  Am J Transl Res       Date:  2020-04-15       Impact factor: 3.940

6.  GATA-4-expressing mouse bone marrow mesenchymal stem cells improve cardiac function after myocardial infarction via secreted exosomes.

Authors:  Ji-Gang He; Hong-Rong Li; Jin-Xiu Han; Bei-Bei Li; Dan Yan; Hong-Yuan Li; Ping Wang; Ying Luo
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.